TG Therapeutics (TGTX) said Tuesday that it expects Q4 Briumvi US net product revenue of $103.6 million.
The company said its cash position at the end of 2024 was $310 million.
TG Therapeutics said it expects 2025 total global revenue of $540 million, including Briumvi US net product revenue of $525 million. Analysts polled by Capital IQ are looking for total revenue of $537.8 million.
Shares of the company were up more than 5% in recent premarket activity.
Price: 29.16, Change: +1.49, Percent Change: +5.38
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。